CTLA4 and acute myeloid leukemia: Durable remissions observed with CTLA-4 blockade in extramedullary AML, and the higher activity of ipilimumab in cancers such as metastatic melanoma, prompted additional investigations into immunologic differences between bone marrow-involved AML, leukemia cutis and solid malignancies.